References
- Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell 2001; 104: 503–516
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16)1685–1695
- Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126
- Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8(11)1218–1226
- Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91(4)281–291
- Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92(3)821–825
- Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16(8)1074–1079
- Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18(12)1972–1982
- George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138(1)147–152
- Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 2005; 96(4)427–434
- Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: Implications for vaccine development. Arterioscler Thromb Vasc Biol 2005; 25(1)18–28
- Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 2000; 247(3)371–380
- Fredrikson GN, Hedblad B, Berglund G, Alm R, Ares M, Cercek B, et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23(5)872–878
- Fredrikson GN, Berglund G, Alm R, Nilsson J-A, Shah PK, Nilsson J. Identification of autoantibodies in human plasma recognizing an apo B-100 LDL receptor-binding site. J Lipid Res 2006; 47(9)2049–2054
- Blesa S, Garcia-Garcia AB, Martinez-Hervas S, Mansego ML, Gonzalez-Albert V, Ascaso JF, et al. Analysis of sequence variations in the LDL receptor gene in Spain: General gene screening or search for specific alterations?. Clin Chem 2006; 52(6)1021–1025
- Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10(3)325–335
- Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003; 23(5)879–884
- Fu T, Mukhopadhyay D, Davidson NO, Borensztajn J. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: Effects on plasma lipoproteins and the development of atherosclerotic lesions. J Biol Chem 2004; 279(27)28662–28669
- Akiyama TE, Lambert G, Nicol CJ, Matsusue K, Peters JM, Brewer HB, Jr, et al. Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J Biol Chem 2004; 279(20)20874–20881
- Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003; 15(4)505–514
- Fredrikson GN, Andersson L, Soderberg I, Dimayuga P, Chyu KY, Shah PK, et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 2005; 38(2)171–179
- Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001; 79(10)552–565